If the candidate biomarker plasmalemmal V-ATPase surpasses all these hurdles and validation steps, it should lead to a tailored application of Lf in cancer therapy, paving the way to precision medicine that will likely prompt clinically effective outcomes. This evidence concerns the gene LTF and cancer.